Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Further Trial Information
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase II | Tissue collection/Repository, Treatment | Active | 18 and over | NCI | NCI-2012-00242 S1117, SWOG-S1117, CDR0000723909, U10CA032102, NCT01522976 |
Summary
This randomized phase II trial studies how well giving azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
Further Study Information
PRIMARY OBJECTIVES:
I. To test whether the response rate (complete remission, partial remission, or hematologic improvement) of patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who receive either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine is improved compared to patients who receive single-agent azacitidine.
II. To estimate relapse-free survival, overall survival and cytogenetic response rate of patients treated on each regimen.
III. To estimate the frequency and severity of toxicities of the three regimens in this patient population.
IV. To investigate in a preliminary manner the frequency of subgroups from pre-study cytogenetic studies and correlate these subgroups with clinical outcomes in this patient population.
V. To collect specimens for banking for use in future research studies.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 or days 1-5 and 8-9, and lenalidomide orally (PO) once daily (QD) on days 1-21.
ARM II: Patients receive azacitidine as in arm I.
ARM III: Patients receive azacitidine as in arm I and vorinostat PO twice daily (BID) on days 3-9.
In all arms, courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Eligibility Criteria
Inclusion Criteria:
- Patients must have morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) based on one of the following:
- French-American-British (FAB) classifications:
- Refractory anemia with excess blasts (RAEB - defined as having 5-20% myeloblasts in the bone marrow)
- CMML with 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
- World Health Organization (WHO) Classifications:
- RAEB-1 (defined as having 5-9% myeloblasts in the bone marrow)
- RAEB-2 (defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood)
- CMML-1 (defined as having < 5% myeloblasts in the bone marrow and/or < 10% blasts in the blood)
- CMML-2 (defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood)
- International prognostic score (IPSS) of Intermediate 2 (1.5-2.0 points) or High (>= 2.5 points); a score of Intermediate 1 (0.5-1.0 points) is only allowable in the setting of >= 5% myeloblasts
- Patients with acute myeloid leukemia (AML) are not eligible
- Procedures to obtain specimens for establishing baseline disease must be done within 30 days prior to registration
- Patients must not have received lenalidomide, azacitidine, vorinostat, or decitabine as treatment previously; any hematopoietic growth factors must be stopped for at least 14 days prior to registration
- Patients may have received low-dose cytarabine for MDS treatment previously, but they must have discontinued its use for at least 28 days prior to registration
- Patients must not have received radiation therapy, chemotherapy, or cytotoxic therapy to treat conditions other than MDS within 12 months prior to registration
- Patients must not have undergone prior allogeneic stem cell or bone marrow transplantation at any time; patients that have undergone an autologous stem cell transplant are eligible
- Patients must not have used or be using histone deacetylase (HDAC) inhibitor agents for anticancer treatment
- Patients may not have received agents such as valproic acid for epilepsy within 30 days prior to registration
- Patients must have Zubrod performance status of 0-2
- Patients must not have any pre-existing neurotoxicity/neuropathy of >= grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0, or prior >= grade 3 allergic reaction/hypersensitivity or rash to thalidomide that has not resolved to < grade 2
- Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving informed consent
- Patients must not have history of thromboembolic event or other condition requiring current use of anticoagulation with Coumadin (warfarin) or low molecular-weight heparin
- Patients must not have known or suspected hypersensitivity to mannitol
- Patients must receive a 12-lead electrocardiogram (EKG), chest x-ray, serum creatinine, complete metabolic panel including serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT), electrolytes, and bilirubin testing within 28 days prior to registration in order to establish baseline measurements; questions regarding patient safety in regards to results of these tests should be directed to the Study Coordinator
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to registration; FCBP must agree to have a second pregnancy test within 24 hours prior to starting course 1 if randomized to receive lenalidomide
- A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patients must commit to the following if they are randomized to receive lenalidomide; FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy
- All patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure
- Patients not randomized to receive lenalidomide will not be required to undergo serial pregnancy testing or lenalidomide counseling after registration
- No prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for three years
- Cytogenetics requirements:
- Southwestern Oncology Group (SWOG) (and other sites not affiliated with Cancer and Leukemia Group B [CALGB] or Eastern Cooperative Oncology Group [ECOG]): Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 14 days prior to registration to SWOG-S1117
- CALGB: CALGB patients must enroll on CALGB 8461, the cytogenetics protocol
- ECOG: Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 30 days prior to registration to S1117
- Banking requirements:
- SWOG and ECOG (and other sites not affiliated with CALGB): Patients must be offered participation in specimen banking
- CALGB: CALGB patients must be offered participation in CALGB 9665, the CALGB Leukemia Tissue bank protocol
- National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG): NCIC CTG patients must be offered participation in specimen submission and banking
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Trial Lead Organizations/Sponsors
National Cancer Institute
| Mikkael Sekeres |  | Principal Investigator |
Trial Sites
|
|
|
|
| U.S.A. | |||
|
|||
| Arizona | |||
|
|||
| Scottsdale | |||
|
|||
| Mayo Clinic Scottsdale | |||
| Mrinal M. Patnaik | Ph: 507-538-7623 | ||
| Mrinal M. Patnaik | Principal Investigator | ||
| Tucson | |||
|
|||
| Arizona Cancer Center at University of Arizona Health Sciences Center | |||
| Ravitharan Krishnadasan | Ph: 520-626-9008 | ||
| Ravitharan Krishnadasan | Principal Investigator | ||
| Ravitharan Krishnadasan | Ph: 520-626-9008 | ||
| Ravitharan Krishnadasan | Principal Investigator | ||
| California | |||
|
|||
| Antioch | |||
|
|||
| Kaiser Permanente-Deer Valley Medical Center | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Duarte | |||
|
|||
| City of Hope Comprehensive Cancer Center | |||
| Margaret R. O'Donnell | Ph: 800-826-4673 | ||
| Email: becomingapatient@coh.org | |||
| Margaret R. O'Donnell | Principal Investigator | ||
| Los Angeles | |||
|
|||
| USC/Norris Comprehensive Cancer Center and Hospital | |||
| Casey L. O'Connell | Ph: 323-865-0451 | ||
| Casey L. O'Connell | Principal Investigator | ||
| Oakland | |||
|
|||
| Kaiser Permanente Medical Center - Oakland | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Richmond | |||
|
|||
| Kaiser Permanente Medical Center - Richmond | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Sacramento | |||
|
|||
| Kaiser Permanente Medical Center - Sacramento | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| South Sacramento Kaiser-Permanente Medical Center | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| San Francisco | |||
|
|||
| Kaiser Permanente Medical Center - San Francisco Geary Campus | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| San Jose | |||
|
|||
| Kaiser Permanente Medical Center - Santa Teresa | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| San Rafael | |||
|
|||
| Kaiser Foundation Hospital - San Rafael | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Santa Clara | |||
|
|||
| Kaiser Permanente Medical Center - Santa Clara Kiely Campus | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| South San Francisco | |||
|
|||
| Kaiser Permanente Medical Center - South San Francisco | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Walnut Creek | |||
|
|||
| Kaiser Permanente Medical Center - Walnut Creek | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| Colorado | |||
|
|||
| Aurora | |||
|
|||
| Medical Center of Aurora - South Campus | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Boulder | |||
|
|||
| Boulder Community Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Colorado Springs | |||
|
|||
| Penrose Cancer Center at Penrose Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Denver | |||
|
|||
| CCOP - Colorado Cancer Research Program | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Porter Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Presbyterian - St. Luke's Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Rose Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| St. Anthony Central Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| St. Joseph Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Englewood | |||
|
|||
| Swedish Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Fort Collins | |||
|
|||
| Front Range Cancer Specialists | |||
| Diana C. Medgyesy | Ph: 970-212-7600 | ||
| Diana C. Medgyesy | Principal Investigator | ||
| Poudre Valley Hospital | |||
| Paolo Romero | Ph: 970-495-8226 | ||
| Paolo Romero | Principal Investigator | ||
| Greeley | |||
|
|||
| North Colorado Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Lone Tree | |||
|
|||
| Sky Ridge Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Longmont | |||
|
|||
| Hope Cancer Care Center at Longmont United Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Loveland | |||
|
|||
| McKee Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Parker | |||
|
|||
| Parker Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Pueblo | |||
|
|||
| St. Mary - Corwin Regional Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Wheat Ridge | |||
|
|||
| Exempla Lutheran Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Eduardo R. Pajon | Principal Investigator | ||
| Connecticut | |||
|
|||
| Hartford | |||
|
|||
| Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center | |||
| Christopher M. Reynolds | Ph: 734-712-3456 | ||
| Christopher M. Reynolds | Principal Investigator | ||
| New Britain | |||
|
|||
| George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus | |||
| James S. Hoffman | Ph: 860-224-5660 | ||
| James S. Hoffman | Principal Investigator | ||
| Delaware | |||
|
|||
| Lewes | |||
|
|||
| Tunnell Cancer Center at Beebe Medical Center | |||
| Stephen S. Grubbs | Ph: 302-733-6227 | ||
| Stephen S. Grubbs | Principal Investigator | ||
| Newark | |||
|
|||
| Helen F. Graham Cancer Center at Christiana Hospital | |||
| Stephen S. Grubbs | Ph: 302-733-6227 | ||
| Stephen S. Grubbs | Principal Investigator | ||
| Florida | |||
|
|||
| Jupiter | |||
|
|||
| Ella Milbank Foshay Cancer Center at Jupiter Medical Center | |||
| Michael A. Schwartz | Ph: 305-674-2625 | ||
| Email: info@msccop.com | |||
| Michael A. Schwartz | Principal Investigator | ||
| Miami Beach | |||
|
|||
| CCOP - Mount Sinai Medical Center | |||
| Michael A. Schwartz | Ph: 305-674-2625 | ||
| Email: info@msccop.com | |||
| Michael Schwartz | Principal Investigator | ||
| Orlando | |||
|
|||
| Florida Hospital Cancer Institute at Florida Hospital Orlando | |||
| Lee M. Zehngebot | Ph: 407-303-5623 | ||
| Lee M. Zehngebot | Principal Investigator | ||
| Georgia | |||
|
|||
| Augusta | |||
|
|||
| Medical College of Georgia Cancer Center | |||
| Anand P. Jillella | Ph: 706-721-1663 | ||
| Email: cancer@georgiahealth.edu | |||
| Anand P. Jillella | Principal Investigator | ||
| Hawaii | |||
|
|||
| Honolulu | |||
|
|||
| Cancer Research Center of Hawaii | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Principal Investigator | ||
| Kaiser Permanente - Moanalua Medical Center and Clinic | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Tatjana Kolevska | Principal Investigator | ||
| OnCare Hawaii, Incorporated - Kuakini | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Principal Investigator | ||
| OnCare Hawaii, Incorporated - Lusitana | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Principal Investigator | ||
| Illinois | |||
|
|||
| Bloomington% | |||
|
|||
| Illinois CancerCare - Bloomington | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Canton | |||
|
|||
| Illinois CancerCare - Canton | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Carthage | |||
|
|||
| Illinois CancerCare - Carthage | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Chicago | |||
|
|||
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |||
| Olga Frankfurt | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Olga Frankfurt | Principal Investigator | ||
| University of Chicago Cancer Research Center | |||
| Olatoyosi M. Odenike | Ph: 773-834-7424 | ||
| Olatoyosi M. Odenike | Principal Investigator | ||
| University of Illinois Cancer Center | |||
| John G. Quigley | Ph: 312-355-3046 | ||
| John G. Quigley | Principal Investigator | ||
| Decatur | |||
|
|||
| Decatur Memorial Hospital Cancer Care Institute | |||
| James L. Wade | Ph: 217-876-4740 | ||
| Email: kcheek@dmhhs.org | |||
| James L. Wade | Principal Investigator | ||
| Eureka | |||
|
|||
| Illinois CancerCare - Eureka | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Evanston | |||
|
|||
| CCOP - Evanston | |||
| Lynne S. Kaminer | Ph: 847-570-1381 | ||
| Lynne S. Kaminer | Principal Investigator | ||
| Havana | |||
|
|||
| Illinois CancerCare - Havana | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Kewanee | |||
|
|||
| Illinois CancerCare - Kewanee Clinic | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Macomb | |||
|
|||
| Illinois CancerCare - Macomb | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Maywood | |||
|
|||
| Cardinal Bernardin Cancer Center at Loyola University Medical Center | |||
| Danielle A. Shafer | Ph: 708-226-4357 | ||
| Danielle A. Shafer | Principal Investigator | ||
| Moline | |||
|
|||
| Trinity Cancer Center at Trinity Medical Center - 7th Street Campus | |||
| Costas L. Constantinou | Ph: 319-363-2690 | ||
| Costas L. Constantinou | Principal Investigator | ||
| Monmouth | |||
|
|||
| Illinois CancerCare - Monmouth | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Normal | |||
|
|||
| Illinois CancerCare - Community Cancer Center | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Ottawa | |||
|
|||
| Illinois CancerCare - Ottawa | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Pekin | |||
|
|||
| Illinois CancerCare - Pekin | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Peoria | |||
|
|||
| CCOP - Illinois Oncology Research Association | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Illinois CancerCare - Peoria | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Peru | |||
|
|||
| Illinois CancerCare - Peru | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Princeton | |||
|
|||
| Illinois CancerCare - Princeton | |||
| Nguyet A. Le-Lindqwister | Ph: 800-793-2262 | ||
| Nguyet A. Le-Lindqwister | Principal Investigator | ||
| Rockford | |||
|
|||
| Swedish-American Regional Cancer Center | |||
| Harvey E. Einhorn | Ph: 815-489-4413 | ||
| Harvey Eric Einhorn | Principal Investigator | ||
| Springfield | |||
|
|||
| Regional Cancer Center at Memorial Medical Center | |||
| James L. Wade | Ph: 217-876-4740 | ||
| Email: kcheek@dmhhs.org | |||
| James L. Wade | Principal Investigator | ||
| Indiana | |||
|
|||
| Merrillville | |||
|
|||
| Premier Oncology Hematology Associates | |||
| Bharat H. Barai | Ph: 219-736-2800 | ||
| Bharat H. Barai | Principal Investigator | ||
| Iowa | |||
|
|||
| Ames | |||
|
|||
| McFarland Clinic, PC | |||
| Joseph J. Merchant | Ph: 515-239-2621 | ||
| Joseph J. Merchant | Principal Investigator | ||
| Iowa City | |||
|
|||
| Holden Comprehensive Cancer Center at University of Iowa | |||
| Thomas H. Carter | Ph: 800-237-1225 | ||
| Thomas H. Carter | Principal Investigator | ||
| Sioux City | |||
|
|||
| Siouxland Hematology-Oncology Associates, LLP | |||
| Donald B. Wender | Ph: 712-252-0088 | ||
| Donald B. Wender | Principal Investigator | ||
| Waterloo | |||
|
|||
| Covenant Cancer Treatment Center | |||
| Mohammed T. Masri | Ph: 319-272-2070 | ||
| Mohammed T. Masri | Principal Investigator | ||
| Kansas | |||
|
|||
| Prairie Village | |||
|
|||
| Kansas City CCOP | |||
| Rakesh Gaur | Ph: 913-948-5588 | ||
| Email: amy.krushelniski@hcahealthcare.com | |||
| Rakesh Gaur | Principal Investigator | ||
| Topeka | |||
|
|||
| Cotton-O'Neil Cancer Center | |||
| David E. Einspahr | Ph: 785-270-4963 | ||
| David E. Einspahr | Principal Investigator | ||
| Kentucky | |||
|
|||
| Lexington | |||
|
|||
| Lucille P. Markey Cancer Center at University of Kentucky | |||
| Dianna S. Howard | Ph: 859-257-3379 | ||
| Dianna S. Howard | Principal Investigator | ||
| Louisiana | |||
|
|||
| Shreveport | |||
|
|||
| Feist-Weiller Cancer Center at Louisiana State University Health Sciences | |||
| Nebu V. Koshy | Ph: 318-813-1412 | ||
| Nebu V. Koshy | Principal Investigator | ||
| Maine | |||
|
|||
| Bangor | |||
|
|||
| CancerCare of Maine at Eastern Maine Medical Center | |||
| Thomas H. Openshaw | Ph: 207-973-4274 | ||
| Thomas H. Openshaw | Principal Investigator | ||
| Maryland | |||
|
|||
| Baltimore | |||
|
|||
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |||
| Steven D. Gore | Ph: 410-955-8804 | ||
| Email: jhcccro@jhmi.edu | |||
| Steven D. Gore | Principal Investigator | ||
| Elkton MD | |||
|
|||
| Union Hospital of Cecil County | |||
| Stephen S. Grubbs | Ph: 302-733-6227 | ||
| Stephen S. Grubbs | Principal Investigator | ||
| Massachusetts | |||
|
|||
| Boston | |||
|
|||
| Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | |||
| David P. Steensma | Ph: 866-790-4500 | ||
| David P. Steensma | Principal Investigator | ||
| Massachusetts General Hospital | |||
| David P. Steensma | Ph: 866-790-4500 | ||
| David P. Steensma | Principal Investigator | ||
| Springfield | |||
|
|||
| Baystate Regional Cancer Program at D'Amour Center for Cancer Care | |||
| Syed S. Ali | Ph: 413-794-3565 | ||
| Email: tamara.wrenn@baystatehealth.org | |||
| Syed S. Ali | Principal Investigator | ||
| Worcester | |||
|
|||
| UMASS Memorial Cancer Center - University Campus | |||
| Muthalagu Ramanathan | Ph: 508-856-2464 | ||
| Email: laura.lefko@umassmed.edu | |||
| Muthalagu Ramanathan | Principal Investigator | ||
| Michigan | |||
|
|||
| Ann Arbor | |||
|
|||
| Saint Joseph Mercy Cancer Center | |||
| Christopher M. Reynolds | Ph: 734-712-3456 | ||
| Christopher M. Reynolds | Principal Investigator | ||
| Detroit | |||
|
|||
| Barbara Ann Karmanos Cancer Institute | |||
| Jay Yang | Ph: 313-576-9363 | ||
| Jay Yang | Principal Investigator | ||
| Escanaba | |||
|
|||
| Green Bay Oncology, Limited - Escanaba | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Grand Rapids | |||
|
|||
| Grand Rapids Clinical Oncology Program | |||
| Gilbert D. Padula | Ph: 616-685-5225 | ||
| Gilbert D. Padula | Principal Investigator | ||
| Iron Mountain | |||
|
|||
| Dickinson County Healthcare System | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Kalamazoo | |||
|
|||
| West Michigan Cancer Center | |||
| Raymond S. Lord | Ph: 269-373-7458 | ||
| Raymond S. Lord | Principal Investigator | ||
| Traverse City | |||
|
|||
| Munson Medical Center | |||
| Gilbert D. Padula | Ph: 616-685-5225 | ||
| Gilbert D. Padula | Principal Investigator | ||
| Minnesota | |||
|
|||
| Bemidji | |||
|
|||
| Sanford Clinic North-Bemidgi | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Preston D. Steen | Principal Investigator | ||
| Burnsville | |||
|
|||
| Fairview Ridges Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Coon Rapids | |||
|
|||
| Mercy and Unity Cancer Center at Mercy Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Edina | |||
|
|||
| Fairview Southdale Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Fridley | |||
|
|||
| Mercy and Unity Cancer Center at Unity Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Hutchinson | |||
|
|||
| Hutchinson Area Health Care | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Maplewood | |||
|
|||
| HealthEast Cancer Care at St. John's Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Minnesota Oncology - Maplewood | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Minneapolis | |||
|
|||
| Hennepin County Medical Center - Minneapolis | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Virginia Piper Cancer Institute at Abbott - Northwestern Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Robbinsdale | |||
|
|||
| Humphrey Cancer Center at North Memorial Outpatient Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Rochester | |||
|
|||
| Mayo Clinic Cancer Center | |||
| Mrinal M. Patnaik | Ph: 507-538-7623 | ||
| Mrinal M. Patnaik | Principal Investigator | ||
| Saint Cloud | |||
|
|||
| CentraCare Clinic - River Campus | |||
| Donald J. Jurgens | Ph: 877-229-4907 | ||
| Email: coborncancercenter@centracare.com | |||
| Donald J. Jurgens | Principal Investigator | ||
| Saint Louis Park | |||
|
|||
| CCOP - Metro-Minnesota | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Park Nicollet Cancer Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Saint Paul | |||
|
|||
| Regions Hospital Cancer Care Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| United Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Shakopee | |||
|
|||
| St. Francis Cancer Center at St. Francis Medical Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Stillwater | |||
|
|||
| Lakeview Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Waconia | |||
|
|||
| Ridgeview Medical Center | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Willmar | |||
|
|||
| Willmar Cancer Center at Rice Memorial Hospital | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Woodbury | |||
|
|||
| Minnesota Oncology - Woodbury | |||
| Patrick J. Flynn | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Patrick J. Flynn | Principal Investigator | ||
| Mississippi | |||
|
|||
| Jackson | |||
|
|||
| University of Mississippi Cancer Clinic | |||
| Stephanie L. Elkins | Ph: 601-815-6700 | ||
| Stephanie L. Elkins | Principal Investigator | ||
| Missouri | |||
|
|||
| Columbia | |||
|
|||
| Ellis Fischel Cancer Center at University of Missouri - Columbia | |||
| Carl E. Freter | Ph: 573-882-7440 | ||
| Carl E. Freter | Principal Investigator | ||
| Kansas City | |||
|
|||
| Saint Luke's Cancer Institute at Saint Luke's Hospital | |||
| Rakesh Gaur | Ph: 913-948-5588 | ||
| Email: amy.krushelniski@hcahealthcare.com | |||
| Rakesh Gaur | Principal Investigator | ||
| Saint Louis | |||
|
|||
| David C. Pratt Cancer Center at St. John's Mercy | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| Bethany G. Sleckman | Principal Investigator | ||
| Montana | |||
|
|||
| Billings | |||
|
|||
| Billings Clinic Cancer Center | |||
| Benjamin T. Marchello | Ph: 800-648-6274 | ||
| Benjamin T. Marchello | Principal Investigator | ||
| Bozeman | |||
|
|||
| Bozeman Deaconess Cancer Center | |||
| Benjamin T. Marchello | Ph: 800-648-6274 | ||
| Benjamin T. Marchello | Principal Investigator | ||
| New Jersey | |||
|
|||
| Camden | |||
|
|||
| Cancer Institute of New Jersey at Cooper University Hospital - Camden | |||
| Stephen S. Grubbs | Ph: 302-733-6227 | ||
| Stephen S. Grubbs | Principal Investigator | ||
| New Mexico | |||
|
|||
| Albuquerque | |||
|
|||
| Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital | |||
| Elizabeth A. McGuire | Ph: 505-727-8000 | ||
| Elizabeth A. McGuire | Principal Investigator | ||
| University of New Mexico Cancer Center | |||
| Elizabeth A. McGuire | Ph: 505-727-8000 | ||
| Elizabeth A. McGuire | Principal Investigator | ||
| New York | |||
|
|||
| Bronx | |||
|
|||
| Albert Einstein Cancer Center at Albert Einstein College of Medicine | |||
| Amit K. Verma | Ph: 718-904-2730 | ||
| Email: aecc@aecom.yu.edu | |||
| Amit K. Verma | Principal Investigator | ||
| Amit K. Verma | Ph: 718-904-2730 | ||
| Email: aecc@aecom.yu.edu | |||
| Amit K. Verma | Principal Investigator | ||
| Buffalo | |||
|
|||
| Roswell Park Cancer Institute | |||
| Eunice S. Wang | Ph: 877-275-7724 | ||
| Eunice Wang | Principal Investigator | ||
| Lake Success | |||
|
|||
| Monter Cancer Center of the North Shore-LIJ Health System | |||
| Cristina M. Ghiuzeli | Ph: 516-562-3467 | ||
| Cristina M. Ghiuzeli | Principal Investigator | ||
| Manhasset | |||
|
|||
| Don Monti Comprehensive Cancer Center at North Shore University Hospital | |||
| Cristina M. Ghiuzeli | Ph: 516-562-3467 | ||
| Cristina M. Ghiuzeli | Principal Investigator | ||
| New York | |||
|
|||
| New York Weill Cornell Cancer Center at Cornell University | |||
| Gail J. Roboz | Ph: 212-746-1848 | ||
| Gail J. Roboz | Principal Investigator | ||
| Rochester | |||
|
|||
| James P. Wilmot Cancer Center at University of Rochester Medical Center | |||
| Jonathan W. Friedberg | Ph: 585-275-5830 | ||
| Jonathan W. Friedberg | Principal Investigator | ||
| North Carolina | |||
|
|||
| Asheboro | |||
|
|||
| Randolph Hospital | |||
| Peter Rubin | Ph: 336-832-0821 | ||
| Peter Rubin | Principal Investigator | ||
| Goldsboro | |||
|
|||
| Wayne Memorial Hospital, Incorporated | |||
| James N. Atkins | Ph: 919-580-0000 | ||
| James N. Atkins | Principal Investigator | ||
| Greensboro | |||
|
|||
| Moses Cone Health System-Regional Cancer Center | |||
| Peter Rubin | Ph: 336-832-0821 | ||
| Peter Rubin | Principal Investigator | ||
| Hendersonville | |||
|
|||
| Pardee Memorial Hospital | |||
| James E. Radford | Ph: 828-696-4716 | ||
| James E. Radford | Principal Investigator | ||
| Kinston | |||
|
|||
| Kinston Medical Specialists | |||
| Peter R. Watson | Ph: 252-559-2200 | ||
| Peter R. Watson | Principal Investigator | ||
| Pinehurst | |||
|
|||
| FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center | |||
| Charles S. Kuzma | Ph: 910-715-2200 | ||
| Charles S. Kuzma | Principal Investigator | ||
| Reidsville | |||
|
|||
| Annie Penn Memorial Hospital | |||
| Peter Rubin | Ph: 336-832-0821 | ||
| Peter Rubin | Principal Investigator | ||
| Statesville | |||
|
|||
| Iredell Memorial Hospital | |||
| Ruby A. Grimm | Ph: 704-873-5661 | ||
| Ruby A. Grimm | Principal Investigator | ||
| North Dakota | |||
|
|||
| Bismarck | |||
|
|||
| Sanford Bismarck Medical Center | |||
| Edward J. Wos | Ph: 701-323-5760 | ||
| Email: tfischer@mohs.org | |||
| Edward J. Wos | Principal Investigator | ||
| Fargo | |||
|
|||
| Roger Maris Cancer Center at MeritCare Hospital | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Preston D. Steen | Principal Investigator | ||
| Sanford Clinic North-Fargo | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Preston D. Steen | Principal Investigator | ||
| Sanford Medical Center-Fargo | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Preston D. Steen | Principal Investigator | ||
| Ohio | |||
|
|||
| Beachwood | |||
|
|||
| Cleveland Clinic Beachwood Family Health and Surgery Center | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Cleveland | |||
|
|||
| Case Comprehensive Cancer Center | |||
| Brenda W. Cooper | Ph: 800-641-2422 | ||
| Brenda W. Cooper | Principal Investigator | ||
| Cleveland Clinic Cancer Center/Fairview Hospital | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Cleveland Clinic Taussig Cancer Center | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Independence | |||
|
|||
| Cleveland Clinic Cancer Center | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Mayfield Heights | |||
|
|||
| Hillcrest Cancer Center at Hillcrest Hospital | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Parma | |||
|
|||
| Parma Community General Hospital | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Sandusky | |||
|
|||
| North Coast Cancer Care, Incorporated | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Strongsville | |||
|
|||
| Cleveland Clinic Cancer Center-Strongsville | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Toledo | |||
|
|||
| University of Toledo Medical Center | |||
| Rex B. Mowat | Ph: 517-265-0116 | ||
| Rex B. Mowat | Principal Investigator | ||
| Wooster | |||
|
|||
| Cleveland Clinic - Wooster | |||
| Anjali S. Advani | Ph: 866-223-8100 | ||
| Anjali S. Advani | Principal Investigator | ||
| Oklahoma | |||
|
|||
| Norman | |||
|
|||
| Cancer Care Associates-Norman | |||
| Vikki A. Canfield | Ph: 888-823-5923 | ||
| Email: ctsucontact@westat.com | |||
| Vikki A. Canfield | Principal Investigator | ||
| Oklahoma City | |||
|
|||
| Cancer Care Associates-Mercy | |||
| Vikki A. Canfield | Ph: 888-823-5923 | ||
| Email: ctsucontact@westat.com | |||
| Vikki A. Canfield | Principal Investigator | ||
| Oklahoma University Cancer Institute | |||
| George B. Selby | Ph: 405-271-4272 | ||
| Email: julie-traylor@ouhsc.edu | |||
| George B. Selby | Principal Investigator | ||
| Oregon | |||
|
|||
| Milwaukie | |||
|
|||
| Providence Milwaukie Hospital | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Newberg | |||
|
|||
| Providence Newberg Medical Center | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Oregon City | |||
|
|||
| Providence Willamette Falls Medical Center | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Portland | |||
|
|||
| Legacy Good Samaritan Hospital & Comprehensive Cancer Center | |||
| Jacqueline Vuky | Ph: 503-299-6500 | ||
| Jacqueline Vuky | Principal Investigator | ||
| Providence Cancer Center at Providence Portland Medical Center | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Providence St. Vincent Medical Center | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Pennsylvania | |||
|
|||
| Allentown | |||
|
|||
| Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest | |||
| Eliot L. Friedman | Ph: 610-402-2273 | ||
| Eliot L. Friedman | Principal Investigator | ||
| Doylestown | |||
|
|||
| Doylestown Hospital Cancer Center | |||
| Mitchell B. Alden | Ph: 215-345-2378 | ||
| Email: lheacock@dh.org | |||
| Mitchell B. Alden | Principal Investigator | ||
| West Reading | |||
|
|||
| McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center | |||
| Terrence P. Cescon | Ph: 610-988-9323 | ||
| Terrence P. Cescon | Principal Investigator | ||
| South Carolina | |||
|
|||
| Greenville | |||
|
|||
| Batson Cancer Care Center at St. Francis Hospital | |||
| James D. Bearden | Ph: 800-486-5941 | ||
| James D. Bearden | Principal Investigator | ||
| Cancer Centers of the Carolinas - Faris | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| Cancer Centers of the Carolinas - Grove Commons | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| CCOP - Greenville | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| Greenville Hospital Cancer Center | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| Greer | |||
|
|||
| Cancer Centers of the Carolinas-Greer Medical Oncology | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| Seneca | |||
|
|||
| Cancer Centers of the Carolinas - Seneca | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| Spartanburg | |||
|
|||
| Cancer Centers of the Carolinas - Spartanburg | |||
| Jeffrey K. Giguere | Ph: 864-241-6251 | ||
| Jeffrey K. Giguere | Principal Investigator | ||
| CCOP - Upstate Carolina | |||
| James D. Bearden | Ph: 800-486-5941 | ||
| James D. Bearden | Principal Investigator | ||
| Gibbs Regional Cancer Center at Spartanburg Regional Medical Center | |||
| James D. Bearden | Ph: 800-486-5941 | ||
| James D. Bearden | Principal Investigator | ||
| South Dakota | |||
|
|||
| Rapid City | |||
|
|||
| Rapid City Regional Hospital | |||
| Mark T. Schroeder | Ph: 605-716-3982 | ||
| Email: research@rcrh.org | |||
| Mark T. Schroeder | Principal Investigator | ||
| Sioux Falls | |||
|
|||
| Sanford Cancer Center at Sanford USD Medical Center | |||
| Miroslaw A. Mazurczak | Ph: 605-328-1367 | ||
| Miroslaw A. Mazurczak | Principal Investigator | ||
| Sanford USD Medical Center - Sioux Falls | |||
| Miroslaw A. Mazurczak | Ph: 605-328-1367 | ||
| Miroslaw A. Mazurczak | Principal Investigator | ||
| Tennessee | |||
|
|||
| Knoxville | |||
|
|||
| Thompson Cancer Survival Center | |||
| Samuel S. McCachren | Ph: 865-541-1812 | ||
| Samuel S. McCachren | Principal Investigator | ||
| Texas | |||
|
|||
| Amarillo | |||
|
|||
| Harrington Cancer Center | |||
| Stewart A. Sharp | Ph: 806-359-4673 | ||
| Email: ryokubaitis@harringtoncc.org | |||
| Stewart A. Sharp | Principal Investigator | ||
| Utah | |||
|
|||
| Salt Lake City | |||
|
|||
| Huntsman Cancer Institute at University of Utah | |||
| Paul J. Shami | Ph: 801-581-4477 | ||
| Email: clinical.trials@hci.utah.edu | |||
| Paul J. Shami | Principal Investigator | ||
| Washington | |||
|
|||
| Vancouver | |||
|
|||
| PeaceHealth Southwest Medical Center | |||
| Alison K. Conlin | Ph: 503-215-6412 | ||
| Alison K. Conlin | Principal Investigator | ||
| Wisconsin | |||
|
|||
| Eau Claire | |||
|
|||
| Marshfield Clinic Cancer Care at Regional Cancer Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Green Bay | |||
|
|||
| Green Bay Oncology, Limited at St. Mary's Hospital | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| St. Mary's Hospital Medical Center - Green Bay | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| St. Vincent Hospital Regional Cancer Center | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center | |||
| Dhimant R. Patel | Ph: 800-252-2990 | ||
| Dhimant R. Patel | Principal Investigator | ||
| Janesville | |||
|
|||
| Mercy Regional Cancer Center | |||
| Emily G. Robinson | Ph: 800-928-1103 | ||
| Emily G. Robinson | Principal Investigator | ||
| La Crosse | |||
|
|||
| Gundersen Lutheran Center for Cancer and Blood | |||
| Kurt Oettel | Ph: 608-775-2385 | ||
| Email: cancerctr@gundluth.org | |||
| Kurt Oettel | Principal Investigator | ||
| Madison | |||
|
|||
| Dean Hematology & Oncology Clinic | |||
| Amit Sanyal | Ph: 608-410-2700 | ||
| Amit Sanyal | Principal Investigator | ||
| Marinette | |||
|
|||
| Vince Lombardi Cancer Clinic - Marinette | |||
| Dhimant R. Patel | Ph: 800-252-2990 | ||
| Dhimant R. Patel | Principal Investigator | ||
| Marshfield | |||
|
|||
| Marshfield Clinic - Marshfield Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Milwaukee | |||
|
|||
| Froedtert Hospital and Medical College of Wisconsin | |||
| Ehab L. Atallah | Ph: 414-805-4380 | ||
| Ehab L. Atallah | Principal Investigator | ||
| Oconomowoc | |||
|
|||
| Regional Cancer Center at Oconomowoc Memorial Hospital | |||
| Michael A. Thompson | Ph: 262-928-7632 | ||
| Michael A. Thompson | Principal Investigator | ||
| Oconto Falls | |||
|
|||
| Green Bay Oncology, Limited - Oconto Falls | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Rhinelander | |||
|
|||
| Ministry Medical Group at Saint Mary's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Rice Lake | |||
|
|||
| Marshfield Clinic - Indianhead Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Stevens Point | |||
|
|||
| Marshfield Clinic Cancer Care at Saint Michael's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Saint Michael's Hospital Cancer Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Sturgeon Bay | |||
|
|||
| Green Bay Oncology, Limited - Sturgeon Bay | |||
| Matthew L. Ryan | Ph: 800-432-6049 | ||
| Matthew L. Ryan | Principal Investigator | ||
| Summit | |||
|
|||
| Aurora Medical Center in Summit | |||
| Dhimant R. Patel | Ph: 800-252-2990 | ||
| Dhimant R. Patel | Principal Investigator | ||
| Waukesha | |||
|
|||
| Waukesha Memorial Hospital Regional Cancer Center | |||
| Michael A. Thompson | Ph: 262-928-7632 | ||
| Michael A. Thompson | Principal Investigator | ||
| Wauwatosa | |||
|
|||
| Aurora Cancer Care-Milwaukee West | |||
| Rubina Qamar | Ph: 888-709-2080 | ||
| Rubina Qamar | Principal Investigator | ||
| Weston | |||
|
|||
| Marshfield Clinic - Weston Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Wisconsin Rapids | |||
|
|||
| Marshfield Clinic - Wisconsin Rapids Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Principal Investigator | ||
| Canada | |||
|
|||
| Ontario | |||
|
|||
| Toronto | |||
|
|||
| Odette Cancer Centre at Sunnybrook | |||
| Rena J. Buckstein | Ph: 416-480-5000 | ||
| Rena J. Buckstein | Principal Investigator | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01522976
Information obtained from ClinicalTrials.gov on April 22, 2013
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
